<DOC>
	<DOCNO>NCT00319163</DOCNO>
	<brief_summary>Primary Objective : To determine bioequivalence clinical batch process new process manufacture LNG/EE . Secondary Objective : To obtain additional safety tolerability data concern LNG/EE healthy , cycling woman .</brief_summary>
	<brief_title>Study Comparing Two Manufacturing Processes Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg ( LNG/EE ) Healthy , Cycling Women</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Women 18 35 year age Nonsmokers History thromboembolic disease Prior adverse experience oral contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>oral contraceptive</keyword>
	<keyword>therapeutic equivalency</keyword>
	<keyword>contraceptive , oral , combine</keyword>
</DOC>